ARPO Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (27 aug 2021 @ 06:00):

Stats
Dagens volum	826 006
Gjennomsnittsvolum	401 776
Markedsverdi	53.67M
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.177 (8.05%)

Insider Trading

Date	Person	Action	Amount	type
2021-06-30	Dalal Anupam	Buy	7 400	Common Stock
2021-06-30	Castelein Caley	Buy	7 811	Common Stock
2021-06-30	Cohen Cheryl	Buy	8 140	Common Stock
2021-06-17	Cohen Cheryl	Buy	100 000	Stock Option (Right to Buy)
2021-03-31	Cohen Cheryl	Buy	8 020	Common Stock

INSIDER POWER
0.00
Last 63 transactions
Buy: 4 252 497 \| Sell: 3 402 072

Volum Korrelasjon

Lang: 0.22 (neutral)

Kort: 0.14 (neutral)

Signal:(54.23) Neutral

Aerpio Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner
RMRM	0.906
GAINL	0.889
KURA	0.84
PETZ	0.838
SEV	0.82
OGI	0.816
SVAC	0.814
THCB	0.813
TLGT	0.811
MBOT	0.808

10 Mest negative korrelasjoner
HWCC	-0.835
BIDU	-0.818
POWL	-0.811
OBAS	-0.808
RXDX	-0.806
LWAC	-0.806
FWONK	-0.806
BNIX	-0.806
BKNG	-0.804
FWONA	-0.803

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Aerpio Pharmaceuticals Korrelasjon - Valuta/Råvare

0.61
( weak )

0.42
( neutral )

0.00
( neutral )

0.19
( neutral )

-0.63
( weak negative )

Aerpio Pharmaceuticals Økonomi

Annual	2022
Omsetning:	$5.51M
Bruttogevinst:	$-29.51M (-535.75 %)
EPS:	$-1.080

FY	2022
Omsetning:	$5.51M
Bruttogevinst:	$-29.51M (-535.75 %)
EPS:	$-1.080

Financial Reports:

No articles found.

Aerpio Pharmaceuticals

Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The company is headquartered in Blue Ash, Ohio and currently employs 27 full-time employees. The firm is focused on developing treatments for ocular disease. Its lead product candidate is AKB-9778. Its other two pipeline programs include AKB-4924 and ARP-1536. AKB-9778 is a small molecule activator of the Tie-2 pathway, which is being developed for the treatment of diabetic retinopathy (DR). AKB-4924 is a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha), which is being developed for the treatment of inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody directed at the same target as AKB-9778. ARP-1536 binds the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibiting its ability to interact with Tie-2. As of April 14, 2017, the Company had completed a Phase II trial of AKB-9778 in 144 patients with diabetic macular edema. As of April 14, 2017, the Company had completed Phase Ia clinical trial in healthy volunteers for AKB-4924.